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Association between virus detection/quantiﬁcation and
clinical signs of airway inﬂammation in horses at
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Previous studies investigating the potential involvement of vi-
ruses in airway inﬂammation were based either on serological
tests or on PCR from nasal swabs only. The objectives of this study
were to determine the incidence of well- and less-characterised
viruses in the equine airways, and their association with clinical
signs. In a 2-year prospective longitudinal study, nasal swabs (NS)
and tracheal washes (TW) were collected monthly on 52 Stan-
dardbred racehorses at training (581 samples). Equine a- and
g-herpesviruses, equine rhinitis virus-A and -B, equine adeno-
virus-A, and equine inﬂuenza virus were investigated by qPCR.
Any positive sample was subcategorised as non-quantiﬁable
(>LOD and <LOQ) or as quantiﬁable (>LOQ). Clinical signs (nasal
discharge, coughing), and tracheal mucus score were simulta-
neously recorded. In TW, respective monthly incidences were
27.9% (EHV-5), 24.8% (EHV-2), 7.1% (ERBV), 3.8% (EHV-4), 1.9%
(EAdV1) and 0.2% (EHV-1, ERAV). EIV has not been detected in any
sample. Molecular detection of EHV-2 and ERBV in TW were
signiﬁcantly associated with coughing (OR 3.1; 95% CI 1.4-7.1;
P¼0.01 and OR 5.3; 95% CI 2.1-14.0; P<0.001, respectively). Posi-
tive samples for EHV-2 in TW were signiﬁcantly associated with
tracheal mucus score 2 (OR 2.1; 95% CI 1.2-3.8; P¼0.02). When
based on quantiﬁable detection, ERBV only was signiﬁcantly
associated with coughing (OR 15.0; 95% CI 3.7-60.0; P<0.001).
Positive samples for any virus in NS were not associated with
clinical signs. Based on our data, detecting ERBV in TW is a major
risk-factor of coughing. This virus should be considered when
investigating horses with inﬂammatory airway disease.
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EHV-1 infections are a world-wide cause of respiratory disease,
late-term abortions and neurological disease. Inactivated and
modiﬁed-live virus (MLV) vaccines are available for protection.
However, availability depends on licensure and regulatory bodies
in each country. The likelihood of (re-) infection in the individual
animal depends on the infectious dose and on pre-existing im-
munity. Here, we investigated aspects of the innate and speciﬁc
mucosal immune responses, as well as the systemic humoralimmune response after intranasal application of an MLV vaccine
(Prevaccinol®; MSD Merck) to animals regularly vaccinated (q6
months) with an inactivated vaccine (Equip®EHV-1,4; Zoetis). Our
hypothesis was that an immune response occurs rapidly after
intranasal application of MLV. Because the potential adverse ef-
fects of intranasal application of an MLV licensed for intramus-
cular application are unknown, we conducted a pilot study in 4
adult animals (2 mules, 2 horses). Clinical data were collected
(rectal temperature (fever > 38.0C), nasal discharge, lymphade-
nopathy), as well as data on viral nasal shedding, systemic and
mucosal antibody production, and (limited) mucosal cytokine
production. Time betweenmost recent IM vaccination and start of
the pilot was 12 weeks. Animals were quarantined on the pre-
mises. Clinical exams were performed daily from the day before
(day -1) until day 7 post intranasal MLV application. Nasal swabs
were collected on days -1, 1, 3, 5 and 7. Blood samples were
collected and serum harvested on days -1, 7, 14 and 21. Nasal swab
samples were subjected to detection of virus shedding using RT-
qPCR, to measurement of total mucosal antibody concentrations
(IgG1, IgG4/7), and to detection of the cytokines IFN-a, IFN-g, IL-4,
IL-10 and IL-17. Virus-neutralising (VN) antibody titres in serum
were determined on days -1, 7, 14 and 21. Nasal discharge was
observed in all 4 animals within 24 hours and until day 4. Fever or
lymphadenopathy was not detected. Virus shedding was low and
occurred in 3/4 animals on day 1 and in 1/4 animals on day 3. IL-
10 and IL-17 were not detected in any sample. IL-4 was more
frequently detected in mules, also prior to MLV application (day
-1). IFN-awas only present in horse’ samples, both before (day -1)
and after intranasal vaccination. IFN-g showed a signiﬁcant in-
crease post intranasal MLV application in all 4 animals. A 3-fold
increase in mucosal antibody concentration was observed in 3/4
animal, 24 hours after intranasal MLV application. Intranasal MLV
application did not have an effect on VN antibody titres. In
conclusion, most animals showed a robust increase in mucosal
antibody titres within 24 hours of intranasal MLV application,
while signiﬁcant side effects and nasal viral shedding wereminor.
Conduction of a full study comparing mucosal immunity between
horses and mules is warranted.Posters
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Infectious diseases afﬂicting the upper respiratory tract are a
major cause of morbidity in young racehorses. The objective of
this study was to identify pathogens associated with acute in-
fectious diseases of the upper respiratory tract affecting a sub-
population of racehorses. To be included, the horses had to be 4
years of age or less. They must have experienced a fever greater
than 102F within 72 hours of the testing period. A rayon tipped
nasal swab was obtained from each nostril. 3 mL of whole blood
was also obtained. The nasal swabs and blood both underwent
qualitative viral DNA/RNA testing via real time PCR. Equine Her-
pes Virus 1 (EHV 1), Equine Herpes Virus 4 (EHV 4), Equine Herpes
Viruses 2 and 5 (EHV 2 & 5), Equine Viral Arteritis (EVA), Equine
Inﬂuenza Virus (EIV), Equine Rhinitis A (ERAV) and B (ERBV) vi-
ruses, Streptococcus equi subsp. Equi, and Adenovirus 1 were
tested for. Datawere captured for 63 horses. Forty-ﬁve horses (45/
61; 74%) were positive for EHV 2 on nasal swab. Forty-four horses
(44/61; 72%) were positive for EHV 5 on nasal swab (Fig.1). Seven
